brochure

Our commitment
Our values
As a leader in orthopaedic innovation,
Corin has pioneered a number of landmark
orthopaedic developments since it was
founded in 1985. We are very proud that we
have been able to improve the quality of life
of hundreds of thousands of patients across
the world through the introduction of these
ground breaking products, and believe this
heritage distinguishes Corin within the global
orthopaedic market.
Quality focus
Our talented and dedicated teams continue
to share a common commitment – delivering
quality orthopaedic products and services to
patients, surgeons and healthcare providers,
which exceed their expectations and positively
impact their lives, through Responsible
Innovation.
Ensuring quality is the primary core value across the business.
Technical excellence
Building and developing talented teams who are experts in
their field.
Creative enthusiasm
Empowering individuals to seek innovative solutions and
continuous improvements.
Responsive support
Responding quickly and resourcefully to our internal and
external customers.
Positive impact
Making a real difference and influencing positive change for
patients, surgeons, healthcare providers and our company.
This is the cornerstone of everything we do.
Responsible Innovation
Our experience
Corin is a world leader in the development, production and
distribution of a wide range of cutting edge, reconstructive
orthopaedic devices. We are committed to finding new and
innovative solutions to positively impact the lives of patients
around the globe.
With an increasingly active and demanding
patient population, the need to provide stateof-the-art conservative treatment pathways,
in addition to more traditional interventions,
has never been more important. Corin’s hip
continuum of care and knee portfolio are
designed to provide each patient with the
optimal solution, utilising some of the most
advanced technologies available in the world to
enhance implant longevity and performance.
Applying our in-house knowledge and
experience, coupled with the know-how of
eminent surgeons, Corin’s innovative product
offering today includes a wide range of cuttingedge brands. Alongside Trinity™ advanced
bearing acetabular cup, MiniHip™ conservative
stem, TriFit TS™ cementless tapered stem,
MetaFix™ cementless stem and TaperFit™
cemented stem, Corin’s pioneering hip portfolio
also incorporates ECiMa™ next generation
vitamin E highly cross-linked polyethylene and
Biomimetic Cementless Technology.
4 |
Unity Knee™ is the most recent addition to
our knee portfolio, which also encompasses
Uniglide™ unicompartmental knee and
Rotaglide+™ total knee. Unity brings a new
dimension to patients and surgeons, helping
to address long-standing issues of patient
satisfaction and wear. Within our wider product
portfolio and further extending our range of
advanced treatment options, Zenith™ total
ankle replacement and LARS™ soft tissue
internal fixation also play an important role in
bringing quality of life to patients.
The growing proportion of people undergoing
joint replacement from the ageing population,
combined with increased expectations for an
active lifestyle, mean that demand for new,
innovative and durable products remains high.
With a reputation for breaking new ground,
Corin’s commitment to restoring quality of life
remains strong, through continued investment
in new technologies and new product
development.
Our focus
With advances in healthcare across the globe
and higher expectations for a sustained quality
of life well into old age, the world is seeing an
ageing, more active population. This in turn is
driving growth in the international orthopaedic
market as the demand for procedures
increases.
In order to support patients and healthcare
professionals around the world, our strategy is
focused on the following areas:
Broaden
Extending our hip and knee portfolio
Innovate
Developing new implant solutions
Strengthen
Increasing our global sales presence
Responsible Innovation | 5
Our geography
Corin has direct operations in eight of the
world’s major orthopaedic markets, with
distribution arrangements in over 30 other
countries.
Corin subsidiaries
Australia
Austria
Germany
Italy
Japan
South Africa
United Kingdom
United States
Global partners
Argentina
Barbados
Belgium
Bolivia
Brazil
Canada
Colombia
Costa Rica
Croatia
Cyprus
Czech Republic
Dominican Republic
Ecuador
Egypt
Ghana
Greece
India
6 |
Israel
Italy
Korea
Lebanon
Malaysia
Mexico
Netherlands
Pakistan
Poland
Portugal
Russia
Spain
Sweden
Thailand
Turkey
United Arab Emirates
Venezuela
Responsible Innovation | 7
Our history
Since its foundation in 1985,
Corin has grown from a small
UK orthopaedic business to a
global orthopaedic solutions
provider with operations in 40
countries worldwide. Throughout
this rapid growth phase Corin
has established a strong
presence across key orthopaedic
segments, providing innovative
and unique solutions to longstanding patient complications
and challenges.
In 2008, a new senior
management team instigated a
five year strategic plan initiating
major investment into new
product development. Since this
time Corin has seen approvals
for its new continuum of care
portfolio in most leading global
markets, including the US,
Europe, South America and
Australia, along with world
leading technology launches
such as ECiMa™ advanced
bearing technology, allowing
better treatment options for active
patients.
8 |
In 2013 Corin was acquired
by the private equity team, 2IL
Orthopaedics, opening up new
opportunities for expansion and
accelerated growth.
■■
Corin is founded in
Cirencester, UK, deriving
its name from the town’s
name in Roman Britain,
Corinium.
1985
■■
Corin USA established.
1992
■■
Corin McMinn hip
resurfacing is launched.
1989
■■
Corin Japan established.
1997
1989
1997
2002
Rotaglide™
Cormet™
Uniglide™
AMC™
knee system is
launched – first true
meniscal bearing knee
system on the market.
hip resurfacing is
launched.
1995
TaperFit™
cemented hip system is
launched.
New knee products
are introduced through
Alphanorm acquisition.
■■
■■
Corin floats on the
London Stock Exchange.
Corin acquires Alphanorm
(later to become Corin
Germany) to gain
presence in the German
and Austrian markets.
2002
■■
Corin achieves sales
in excess of £20m.
2003
New senior management
team embark on renewed
five year strategic plan with
major investment in new
product development.
Corin expands UK
headquarters to new site.
■■
■■
Corin Australia
established.
■■
2004
■■
Corin achieves sales in
excess of £40m.
Collaboration with a
leading research institute
to develop ECiMa™
next-generation vitamin E
technology.
Global supply agreement
signed with MAKO Surgical
Corp, to provide total hip
solutions for the Rio™
interactive robotic system.
2009
2010
■■
■■
2008
FDA approval for
Cormet™ in the USA.
■■
2007
■■
Corin acquired by
2IL Orthopaedics,
opening new
opportunities for growth.
2013
■■
Corin South Africa and
Corin Italy established.
2014
2008
2009
2011
2012
2014
MetaFix™
Zenith™
MiniHip™
ECiMa™
Unity Knee™
Revival™
cementless hip and total
ankle system are launched.
bone conserving hip
system is launched.
next generation
vitamin E technology
is launched.
2010
Trinity™
advanced bearing
acetabular cup system
is launched.
revision hip platform
introduced to the Corin hip
continuum of care.
the world’s first fifth
generation knee system
launched.
2013
blade stem based on
extensive global CT patient
data is launched.
Responsible Innovation | 9
Our hip portfolio
Today’s patients expect, and deserve, to have
access to the very latest treatment options.
With a global population that is living longer
and becoming more active, the need to ensure
conservative and effective treatment pathways
has never been more important.
Corin’s hip continuum of care is designed to
provide each patient with the optimal patient
matched solution, using some of the most
advanced bearing technologies in the world.
Trinity™
Advanced Bearing Acetabular System
MiniHip™
Bone Conserving Hip Replacement
Cementless Tapered Hip Replacement
MetaFix™
Cementless Total Hip Replacement
TaperFit™
Cemented Total Hip Replacement
Revival™
Modular Revision Hip System
10 |
Responsible Innovation | 11
Our knee portfolio
Corin has long established its credentials in
providing unique world class knee solutions.
Learning from the experience of over 40 years
of total knee development, Unity Knee™ is
the latest evolution in total knee arthroplasty –
unifying key design technologies with advanced
knee kinematics, soft tissue preservation
concepts and modern surgical principles.
Unity joins our portfolio alongside Uniglide™,
one of the most comprehensive mobile and
fixed bearing unicompartmental knee offerings,
Rotaglide+™, the world’s first truly mobile knee
system, and AMC II™ total knee platform.
Uniglide™
Unicompartmental Knee Replacement
Unity Knee™
Total Knee System
Rotaglide+™
Total Knee System
AMC II™
Total Knee System
12 |
Our wider portfolio
Zenith™ total ankle replacement provides a high
performance alternative to ankle fusion. Together
with an innovative implant design concept,
advanced material technology and state of the
art instrumentation, Zenith™ is designed to
restore confidence in total ankle surgery.
LARS™ is one of the most advanced nonbiological soft tissue treatment options, providing
a conservative alternative to the need to harvest
existing soft tissues.
Zenith™
Total Ankle Replacement
LARS™
Soft Tissue Internal Fixation
Solomax™
Pulsed Lavage System
Responsible Innovation | 13
Our technology
Corin has developed a worldwide network of research associations
with leading universities, research institutes and industrial partners,
ensuring that we stay at the forefront of innovation.
State of the art test methodologies are used
to develop and verify new technologies to
demonstrate the safety and efficacy of all our
prostheses. Advanced computer simulation
technologies model and predict the lifecycle
of prostheses, whilst kinematic analysis and
mechanical simulations are used to replicate
patients’ behaviour, ensuring that product
performance is optimised over the life of the
implant.
Research into new materials allows us to offer
world first technologies for the next decade
through developing products based on the
very best in implant technology, designed to
enhance longevity and performance. The focus
of research concentrates on providing patient
benefits to improve quality of life in a society of
increasingly active arthritic patients – minimising
wear, addressing aseptic loosening and
reducing stress shielding that can cause bone
loss around implants and increased revision
rates.
Corin has a first class track record of gaining
access to external grant funding (Technology
Strategy Board, NIHR i4i and EU funding) and
14 |
running multidisciplinary research projects with
a clear end goal – to develop products for
improved patient function and benefit.
Research outputs are disseminated at
international conferences and via publications
in peer-reviewed journals in collaboration with
our global research partners and key opinion
leaders.
ECiMa™
In a unique collaboration, Corin has worked with a leading
research institute on the development and commercialisation
of a next generation vitamin E polyethylene. The result,
ECiMa™, is a cold-irradiated, mechanically-annealed,
vitamin E-blended ultra high molecular weight polyethylene
(UHMWPE).
The most advanced polyethylene of its kind, ECiMa™
has been developed to minimise wear, improve oxidation
resistance in today’s
increasingly younger and
more active patients,
and to offer mechanical
properties superior
to other conventional
highly cross-linked
polyethylenes due to its
unique process.
Global collaboration
Corin is engaged in world class collaborations with global
innovation leaders in the pursuit of the ‘forgotten implant’ – an
implant offering such performance that the patient forgets its
presence. Next generation porous implants with enhanced
fixation and bone adaptive structures that minimise stress
shielding are being specifically developed for the increasingly
younger and more active demographic. Such implants have
optimised micro-textured surfaces to improve initial stability
and secure rapid osseointegration. The ‘forgotten implant’ will
offer increased functionality and longevity, and as research
continues will represent the next major advancement in
implant technology.
Responsible Innovation | 15
16 |
Our operation
An example of British manufacturing success, all production takes place on-site at our UK
headquarters. Our facilities have consistently been updated over the years to encompass the very
latest manufacturing technologies and modern production principles, ensuring all Corin products meet
the very highest standards in quality engineering.
The combination of modern manufacturing
methodologies alongside continued investment
in high tech computer-controlled machinery
ensures the highest level of operational
efficiency. This enables us to produce quality
products, ensuring the best patient outcomes
for our global operating partners.
Corin operates in a highly regulated environment
with frequent and thorough external quality
audits to ensure our continuing compliance with
relevant statutory and industry standards. All
products are designed to be safe and reliable
and comply with, or exceed, all legal and
regulatory requirements.
Coupled with this quality and technology is
a highly skilled and motivated workforce.
Our teams combine experienced individuals
who have been in medical manufacturing for
many years, with the ongoing development of
the best local talent through an effective and
well-established apprenticeship programme,
developed in conjunction with a local university.
We have a strong environmental, health and
safety awareness across all areas of our
business, anticipating future requirements so that
the health and safety of customers and patients
is continually enhanced. In an ever-competitive
market, the culture within Corin encourages
people at all levels to engage in an environment
of continuous improvement, positively impacting
on the growth and development of Corin.
Quality is a core value deeply embedded
within Corin’s culture across all aspects of the
organisation and every product is subject to
the highest level of quality assurance. Today,
computer aided technology is central to all
aspects of our business, from the creation of the
initial concept ideas through to the manufacture
and measurement of all components using
computer-controlled coordinate measuring
machines (CMMs) and high-end vision systems.
Responsible Innovation
17
Our support
Corin Academy was established to provide a wide range of
surgeon training initiatives to meet the needs of the changing global
orthopaedic community.
Through a range of meeting and education
formats, our vision is to provide a forum to debate
and discuss current concepts and best practice in
orthopaedic surgery, and to help build long-term
clinical success for today’s patient population.
We deliver this through the following initiatives:
The eExpert
Surgeon eLearning
The Visit
Centres of Excellence
The Experience
Live surgery
The Masterclass
Expert guidance
The Science
Surgeon-led congress
The Lab
Cadaveric workshops
The Forum
Sharing best practice
18 |
Surgeon to surgeon visits
The ‘Experience’ meeting
Utilising the most highly-skilled practitioners to
train surgeons on each procedure ensures that
best practice is passed on, enabling excellent
clinical performance and promoting long-term
patient wellbeing as well as outstanding clinical
results for Corin manufactured products.
Surgeon to surgeon hospital visits offer highly
effective one-on-one training opportunities
allowing experts to discuss products which
are at the foreground of modern orthopaedic
practice. These exchanges facilitate
opportunities for knowledge transfer in a live
theatre environment.
Scientific congresses
Modern orthopaedic medicine depends on
a lively interaction between experts in this
ever-changing field. In order to promote such
discussion, Corin works diligently with a wide
faculty of experts who are able to work with
us to put together the most interesting and
topical agendas and debates, whilst seeking to
drive understanding and illuminate those areas
requiring clarity.
Through this close interaction with experts,
Corin has been able to stay at the cutting edge
of orthopaedic practice, to better understand
the needs of surgeons and their patients.
Each year, the Corin Academy
meeting calendar includes the
successful ‘Experience’ series.
Through recognising the importance
of a wide range of inputs and
utilising these, we are able to make
rapid progress with delegates and
help them to greatly improve their
understanding of products and
procedures in a well-controlled
environment.
By using an innovative mixture of live
video-link surgery, didactic sessions
and dry-bone workshops, as well as
interactive sessions such as ‘difficult
cases’ and ‘what would you do?’,
delegates feel that they are able to
get the best out of meetings and
the valuable time away from their
practices.
Responsible Innovation | 19
20 |
Our service
JointResponse™ provides a wide range of innovative
reconstructive orthopaedic solutions on a short-term loan basis,
working with client hospitals to help them meet their commitments
to patients.
Corin’s highly trained and professional
JointResponse customer support team works in
partnership with client hospitals to understand
requirements, delivering a personal level of
service to meet the exact needs of all our
individual customers.
a wealth of experience, the dedicated inhouse JointResponse team understands the
importance of peace of mind. Whenever an
order is placed with one of our friendly and
helpful members, you can be assured of a fast,
efficient and reliable response.
Implants spanning a range of sizes and
associated instrumentation are dispatched to
the hospital for the duration of surgery and
then returned back to Corin. Loan kits are sent
out on a guaranteed next morning delivery or
they can also be fast-tracked for more urgent
requirements.
Instrumentation is maintained to the highest
standard and supplied in high quality, custombuilt flight cases. Our comprehensive storage
system and excellent cleaning facilities ensure
that all orders are serviced promptly and
accurately. All loan kits are supplied fullyfunctional and decontaminated.
We know how important it is that the right
implants, together with the right instrumentation,
are delivered at exactly the right time. With
Responsible Innovation | 21
Our clinical responsibility
As an organisation, Corin places a great deal of importance on
collaboration with key clinical institutions to deliver strong medical
research programmes that support the safe and effective use of
Corin implants.
Being at the cutting edge of new product
development and also with well-established
products in our portfolio, Corin has the dual
responsibility of dealing with new product
introductions as well as the changing face of the
global regulatory systems relating to in-market
devices.
Taking our responsibility for patient wellbeing
seriously means investing significantly in short,
medium and long-term studies of up to 15
years’ duration. As a company we support
registries both locally and globally as well as
single and multi-centre, international data
collections, in order to monitor the safe and
effective use of our devices worldwide.
Over recent years we have implemented a
dramatic increase in the level of clinical research
activity carried out in relation to Corin’s devices.
This has been driven by regulatory imperatives
and the requirement to support the launch of
a series of new hip products through global
multi-centre initiatives. As we drive forward, we
will continue to develop innovative products in a
responsible manner.
22 |
Our dedication to clinical data collection is
strongly aligned to our enthusiasm for surgeon
training, for it can only be by the combination of
these two key elements that we will be able to
produce long-term clinical efficacy and patient
satisfaction.
We will continue to invest significantly in robust
clinical research in partnership with leading
global clinical centres to document the safe
and effective use of Corin’s implants – both for
surgeons and their patients.
Responsible Innovation | 23
24 |
Our corporate responsibility
Corin is committed to carrying out its operations in a socially and environmentally responsible way. In all
aspects of our operations and dealings with customers, business partners, employees, shareholders
and the local community, we recognise the importance of corporate responsibility both to our
stakeholders and to the long-term success of our business.
Our responsibilities to our customers are of paramount importance as
we continue to develop and expand our range of products. We provide
education and training support for healthcare professionals and maintain
a significant investment in research and development. Our products are
designed to be safe and reliable, complying with or exceeding all legal and
regulatory requirements.
Environmentally we recognise the need to protect and preserve the
world’s resources and accept our obligations as an organisation to identify
and, as far as practicable, to reduce, re-use and recycle any aspect of our
activities, products and services that could potentially have an adverse
environmental impact. We are committed to comply with all applicable
environmental legislation and actively maintain an environmental
management system which meets the requirements of ISO 14001.
Corin has a formal code of conduct providing guidelines for employees
regarding business behaviour, interactions with healthcare professionals,
conflicts of interest and the use of intellectual property, information and
company resources. We offer employees the encouragement to learn and
progress, fairly recognising and rewarding performance. Our recruitment
and promotion policies are based solely on qualifications and abilities and
we do not tolerate discrimination on any grounds.
All operations are conducted in accordance with generally accepted
principles and rules of good governance and we aim to provide sustained,
profitable growth to our shareholders, valuing their views and recognising
their interest in the Group’s strategy and performance. We provide regular
information on our activities, structure, financial situation and performance.
Corin considers that making a contribution to the communities in which
we are based is an important commitment and we support employees
who undertake voluntary or community work. We contribute to a number
of charitable causes each year, focusing on the provision and promotion
of health and welfare services both within the local community and further
afield in some of the world’s less developed countries.
Responsible Innovation
25
Our future
Through sustained investment in our core
values, Corin continues to bring benefits to
hundreds of thousands of people, delivering
on our commitment to provide treatment
options that exceed the expectations
and positively impact the lives of patients,
surgeons and healthcare providers around
the world.
Responsible Innovation is the cornerstone
of everything we do and drives our vision
and dedication to become one of the most
respected orthopaedic medical device
companies in the world.
26 |
The Corinium Centre
Cirencester, GL7 1YJ
United Kingdom
t: +44 (0)1285 659 866
f: +44 (0)1285 658 960
e: info@coringroup.com
www.coringroup.com
This document has been printed in the UK on Novatech Matt paper which is sourced from FSC® Chain of Custody responsibly
managed forests. The paper is produced at a mill which holds certifications for ISO 9001 Quality Management System, ISO 14001
Environmental Management Standard and the Carbon Trust Standard. The pulp is bleached using Elemental Chlorine Free processes.
If you have finished reading this report and no longer wish to retain it, please pass it on to other interested readers; return it to Corin
or dispose of it in your recycled paper waste. Thank you.
Responsible Innovation
©2015 Corin P No. I1187 Rev3 02/2015 ECR 13699
Responsible Innovation